Wednesday, July 26, 2017 10:25:18 AM
Advisory Services
On October 3, 2013, the Company entered into an agreement with Ian Thompson for strategic business advisory services, public relations services and investor relations services with Ian Thompson. In connection with this agreement, the Company issued 167,204 shares of restricted Common Stock and recorded consulting fees of $501,612 during 2013, which was the fair market value of the stock on the date of issue. The stock is vested; however it is restricted from trading. Ian Thompson was also issued 200,000 shares of restricted Common Stock, which was to vest quarterly based upon the Company reaching certain market capitalization and revenue goals, in addition to providing the above services, with the last tranche vesting scheduled to vest on June 30, 2014. Consulting fees amounting to $105,000 and $280,000 were recorded in 2014 and 2013, respectively, related to the 200,000 shares of Common Stock. Throughout the term of the agreement, the Company requested that Ian Thompson render performance under the agreement and to provide evidence of same. Ian Thompson failed to perform in all material respects under the terms of the agreement and refused to provide evidence.
On June 27, 2014, the Company terminated the agreement. The Company is taking all necessary steps for the cancellation of the 367,204 shares, due to lack of delivery of consideration and material breach of the agreement
Recent MOJO News
- Form 8-K - Current report • Edgar (US Regulatory) • 01/10/2024 11:02:02 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/15/2023 03:35:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/04/2023 02:00:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/01/2023 04:00:25 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/18/2023 01:42:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/02/2023 05:12:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/07/2023 06:00:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/03/2023 01:52:40 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/02/2023 05:10:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/30/2023 09:00:21 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM